- Home
- PERI vs ZBIO Comparison
PERI vs ZBIO Comparison
Compare PERI & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERI
- ZBIO
- Stock Information
- Founded
- PERI 1999
- ZBIO 2019
- Country
- PERI Israel
- ZBIO United States
- Employees
- PERI N/A
- ZBIO N/A
- Industry
- PERI EDP Services
- ZBIO
- Sector
- PERI Technology
- ZBIO
- Exchange
- PERI Nasdaq
- ZBIO NYSE
- Market Cap
- PERI 457.1M
- ZBIO 504.9M
- IPO Year
- PERI 2006
- ZBIO 2024
- Fundamental
- Price
- PERI $11.04
- ZBIO $13.35
- Analyst Decision
- PERI Buy
- ZBIO Strong Buy
- Analyst Count
- PERI 4
- ZBIO 7
- Target Price
- PERI $11.83
- ZBIO $32.29
- AVG Volume (30 Days)
- PERI 243.9K
- ZBIO 185.3K
- Earning Date
- PERI 08-11-2025
- ZBIO 08-16-2025
- Dividend Yield
- PERI N/A
- ZBIO N/A
- EPS Growth
- PERI N/A
- ZBIO N/A
- EPS
- PERI N/A
- ZBIO N/A
- Revenue
- PERI $429,808,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- PERI N/A
- ZBIO $165.20
- Revenue Next Year
- PERI $11.24
- ZBIO $63.75
- P/E Ratio
- PERI N/A
- ZBIO N/A
- Revenue Growth
- PERI N/A
- ZBIO N/A
- 52 Week Low
- PERI $7.00
- ZBIO $5.83
- 52 Week High
- PERI $11.79
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- PERI 60.28
- ZBIO N/A
- Support Level
- PERI $10.80
- ZBIO N/A
- Resistance Level
- PERI $11.25
- ZBIO N/A
- Average True Range (ATR)
- PERI 0.27
- ZBIO 0.00
- MACD
- PERI 0.03
- ZBIO 0.00
- Stochastic Oscillator
- PERI 76.89
- ZBIO 0.00
About PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.